Akèy › Kansè Poumon ki pa ti selil › New York › Albany
Etid klinik pou Kansè Poumon ki pa ti selil nan Albany, NY
9 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Albany (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Ap rekriteFaz 3
- New York Oncology Hematology, P.C. ( Site 0132), Albany
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Ap rekriteFaz 3
- New York Oncology Hematology, P.C. ( Site 0119), Albany
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- New York Oncology Hematology, P.C. ( Site 9000), Albany
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Ap rekriteFaz 3
- New York Oncology Hematology P.C ( Site 9000), Albany
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- New York Oncology Hematology, Albany
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- New York Oncology Hematology - Albany Medical Center, Albany
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- ONE Onc: New York Oncology Hematology, Albany
MYLUNG Consortium Part 3: Observational Study
Ap rekriteEtid obsèvasyon
- New York Oncology Hematology, P.C., Albany
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- New York Oncology Hematology, Albany
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Albany
- Maladi kadyovaskilè7 etid
- Ensifizyans kadyak6 etid
- Obèsite6 etid
- Kansè (tout kalite)5 etid
- Akidan serebavaskilè4 etid
- Hypertension artérielle4 etid
- Limfòm Burkitt4 etid
- Myelom Miltip4 etid
- Maladi Alzheimer4 etid
- Maladi Dijestif4 etid
- Kansè vejik4 etid
- Kansè nan tete4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.